Orphazyme(OZYMF)
$90.000.00 (0.00%)
OZYMF
Orphazyme financials statements
$90.00
At close:0.00 (0.00%)
Orphazyme (OZYMF) Ratios
12 Followers
Orphazyme Ratios
OZYMF's free cash flow for Q2 2026 was kr-1.34M. For the 2026 fiscal year, OZYMF's free cash flow was increased by kr0.00 and operating cash flow was kr-1.34M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.90 | 4.64 | 3.81 | 3.61 | 1.23 |
| Quick Ratio | 13.90 | 4.64 | 3.81 | 3.61 | 1.23 |
| Cash Ratio | 0.34 | 0.90 | 2.22 | 2.47 | 0.79 |
| Solvency Ratio | -0.75 | -0.07 | -4.98 | -6.93 | -3.71 |
| Operating Cash Flow Ratio | -1.86 | -0.78 | -0.00 | -6.63 | -4.67 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -19.45 |
| Net Current Asset Value | kr 14.82M | kr 15.70M | kr 14.24M | kr 40.97M | kr -4.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 4.28 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.81 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 |
| Financial Leverage Ratio | 1.06 | 1.22 | 1.36 | 1.39 | 18.55 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -14.76 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8.69 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 1419.45 |
| Net Debt to EBITDA | 0.16 | 19.33 | 0.93 | 0.96 | 0.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 0.00% | 0.00% | 0.00% | 49.96% |
| EBIT Margin | -791.59% | 0.00% | 0.00% | 0.00% | -1718.63% |
| EBITDA Margin | -791.59% | 0.00% | 0.00% | 0.00% | -1668.59% |
| Operating Profit Margin | -791.59% | 0.00% | 0.00% | 0.00% | -230.63% |
| Pretax Profit Margin | -277.99% | 0.00% | 0.00% | 0.00% | -230.53% |
| Net Profit Margin | -277.99% | 0.00% | 0.00% | 0.00% | -1731.11% |
| Continuous Operations Profit Margin | -277.99% | 0.00% | 0.00% | 0.00% | -216.88% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 269.37% | 750.92% |
| EBT Per EBIT | 35.12% | 148.26% | 96.33% | 99.55% | 99.96% |
| Return on Assets (ROA) | -4.40% | -1.26% | -134.88% | -194.62% | -361.68% |
| Return on Equity (ROE) | -4.67% | -1.55% | -182.90% | -269.91% | -6708.84% |
| Return on Capital Employed (ROCE) | -13.30% | -1.04% | -189.87% | -100.41% | -189.12% |
| Return on Invested Capital (ROIC) | -13.30% | -1.04% | -189.86% | -93.68% | -101.07% |
| Return on Tangible Assets | -4.40% | -1.26% | -134.88% | -194.62% | -366.23% |
| Earnings Yield | -2.95% | -0.97% | -8.29% | -51.31% | -15.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.83 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.18 | 0.43 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 4.30 |
| Asset Turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.21 |
| Working Capital Turnover Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -2033.64 | -400.15 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 441.89 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 2033.64 | 842.03 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 441.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -51.21 | -90.53 | -0.57 | -2963.40 | -17253.78 |
| Free Cash Flow Per Share | -51.21 | -90.53 | -0.57 | -3344.15 | -17282.24 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -7.78 | -606.21 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -7.78 | -606.21 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -15.08 |
| Operating Cash Flow to Sales Ratio | -6.91 | 0.00 | 0.00 | 0.00 | -16.65 |
| Free Cash Flow Yield | -7.34% | -10.97% | -0.01% | -54.72% | -15.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -33.24 | -103.14 | -12.07 | -1.95 | -6.25 |
| Price-to-Sales (P/S) Ratio | 94.22 | 0.00 | 0.00 | 0.00 | 108.25 |
| Price-to-Book (P/B) Ratio | 1.58 | 1.59 | 22.07 | 5.26 | 419.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.63 | -9.11 | -15698.98 | -1.83 | -6.49 |
| Price-to-Operating Cash Flow Ratio | -13.63 | -9.11 | -15698.98 | -2.06 | -6.50 |
| Price-to-Earnings Growth (PEG) Ratio | -0.20 | -0.11 | 0.16 | 0.02 | 0.32 |
| Enterprise Value Multiple | -11.74 | -133.06 | -25.04 | -4.37 | -6.38 |
| Enterprise Value | 28.72M | 26.75M | 303.04M | 176.64M | 3.86B |
| EV to EBITDA | -11.74 | -133.06 | -25.04 | -4.37 | -6.38 |
| EV to Sales | 92.95 | 0.00 | 0.00 | 0.00 | 106.53 |
| EV to Free Cash Flow | -13.45 | -7.96 | -15136.12 | -1.50 | -6.39 |
| EV to Operating Cash Flow | -13.45 | -7.96 | -15136.12 | -1.69 | -6.40 |
| Tangible Book Value Per Share | 440.88 | 518.46 | 406.91 | 1161.76 | 205.82 |
| Shareholders’ Equity Per Share | 440.88 | 518.46 | 406.91 | 1161.76 | 267.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.07 | 0.06 |
| Revenue Per Share | 7.41 | 0.00 | 0.00 | 0.00 | 1036.34 |
| Net Income Per Share | -20.59 | -8.03 | -744.23 | -3135.73 | -17940.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 2.69 | 7.51 |
| Interest Burden | 0.35 | 1.48 | 2.02 | 1.00 | 0.13 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 6.35 |
| SG&A to Revenue | 1.45 | 0.00 | 0.00 | 0.00 | 11.64 |
| Stock-Based Compensation to Revenue | 0.27 | 0.00 | 0.00 | 0.00 | 0.44 |
| Income Quality | 2.49 | 16.72 | 0.77 | 2.73 | 0.96 |
Currency in DKK
